The balance of concurrent aggregation and deaggregation processes in platelets is linked to differential occupancy of ADP receptor subtypes

Platelets

Volumn 12, Issue 2, 2001, Pages 83-93

  Maayani, S ^a   Tagliente, T M ^a   Schwarz, T ^a   Martinelli, G ^a   Martinez, R ^a   Shore Lesserson, L ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; HIRUDIN; RECEPTOR SUBTYPE;

ADULT; ARTICLE; COMPARTMENT MODEL; FEEDBACK SYSTEM; FEMALE; HUMAN; HUMAN CELL; KINETICS; MALE; OPTICAL DENSITY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

ADENOSINE DIPHOSPHATE; ADULT; CALCIUM SIGNALING; CELL COMPARTMENTATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; KINETICS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MODELS, BIOLOGICAL; PLATELET AGGREGATION; RECEPTORS, PURINERGIC P2; THIONUCLEOTIDES;

EID: 0035071178     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537100020032846     Document Type: Article

References (53)

1. Aggregation of blood platelets by adenosine diphosphate and its reversal
2. The aggregation of blood platelets
3. ADP can induce aggregation of human platelets via both P2Y(1) and P-2T receptors
4. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood
5. ADP-induced refractory state of platelets in vitro - I. Methodological studies on aggregation in platelet rich plasma
6. Aggregation and disaggregation kinetics of human blood platelets: Part I. Development and validation of a population balance method
7. Agonist-specific refractory states of bovine platelets-disappearance of synergism in aggregation
8. Possible mechanism of aggregation of blood platelets by adenosine diphosphate
9. Kinetic studies of desensitization and resensitization of the relaxation response to beta-2 adrenoceptor agonists in isolated guinea pig trachea
10. Effect of adenine compounds on platelet aggregation
11. Adenine nucleotide metabolism of blood platelets. IV. Platelet aggregation response to exogenous ATP and ADP
12. Inhibitors of ADP-induced platelet aggregation prevent fibrinogen binding to rabbit platelets and cause rapid deaggregation and dissociation of bound fibrinogen
13. The influence of epinephrine on prostacyclin (PGI2) induced dissociation of ADP aggregated platelets
14. Disaggregation and reaggregation of 'irreversibly' aggregated platelets: A method for more complete evaluation of anti-platelet drugs
15. A compartmental model of platelet aggregation in vitro: The kinetics of single platelets
16. 2 receptors in isolated rabbit aorta
17. 2) receptor in the isolated rabbit aorta
18. Functional interactions in smooth muscle: Kinetic characterization of the relaxation and desensitization responses to a beta adrenergic agonist in the rabbit aorta
19. Molecular basis for ADP-induced platelet activation I. Evidence for three distinct ADP receptors on human platelets
20. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors
21. Multiple P2 receptor subtypes on platelets: A new interpretation of their function
22. T purinoceptors in human platelets
23. More pieces of the platelet activation puzzle slide into place
24. Platelet aggregation monitored in a 96 well microplate reader is useful for evaluation of platelet agonists and antagonists
25. Measuring platelet aggregation with microplate reader. A new technical approach to platelet aggregation studies
26. Optimisation of platelet aggregometry utilising micotitreplate technology and integrated software
27. Microplate reader - A convenient tool in studies of blood coagulation
28. 1A and adenosine A1 receptor systems in rat hippocampal membranes
29. 2-Methylthioadenosine[beta-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets
30. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function
31. The anti-aggregatory effects of clopidogrel are due to enhancement of platelet deaggregation
32. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation
33. Effects of adrenaline on human blood platelets
34. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation
35. 1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors
36. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
37. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate
38. 1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets
39. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors
40. A mathematical model for optical platelet aggregation test
41. A study of the kinetics of ADP-triggered platelet shape change
42. A study of the kinetics and mechanism of ADP-triggered platelet aggregation
43. Mathematical correlation between ADP-induced platelet aggregation and subsequent disaggregation. A parameter for the velocity of disaggregation
44. Kinetic parameters of platelet aggregation as an expression of platelet responsiveness
45. Differences in platelet aggregation kinetics in normal and hyperlipidemic rabbits
46. 1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel
47. 1 purinoceptor in ADP-induced platelet activation
48. Cell response kinetics: The phenomenon of supercooperativity in aggregation of human platelets
49. Platelet ADP receptor and alpha 2-adrenoreceptor interaction. Evidence for an ADP requirement for epinephrineinduced platelet activation and an influence of epinephrine on ADP binding
50. Evidence for the dependence of arterial haemostasis on ADP
51. Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in nonhuman primates
52. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries